Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET…
Out of more than 5,000 applications: IOC Young Leaders Programme welcomes 25 new recruits for 2025 to 2028
19 February 2025 - After receiving an overwhelming number of more than 5,000…
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)
February 18, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Sparekassen Kronjylland, number one in customer satisfaction, signs Agillic to raise the bar
February 18, 2025 04:37 ET | Source: Agillic A/S Press release, Copenhagen,…
TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant
TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results…
adidas Icon, Son HeungMin, Surprises London Youth Football Organisation to Help Players Believe, You Got This
adidas has revealed the positive behaviors that athletes need from coaches, parents,…
XRP Shows Resilience Amid Market Volatility, Join The Private Sale Round of XRPs First Launchpad – BlocScale
LIJA, Malta, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Over the week, XRP…
iPower Reports Fiscal Second Quarter 2025 Results
February 13, 2025 16:05 ET | Source: iPower, Inc. Fiscal Q2 Revenue…
Creative Medical Technology Reports Positive One-Year Results for AlloStem Type 2 Diabetes Program
Significant Efficacy and No Serious Adverse Effects Observed with CELZ-201 February 11,…
EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior…